Matter of Time is directed by Matt Finlin, who previously helmed The Movie, which Deadline’s Pete Hammond called a “Canadian ...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--#Biotech--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing ...

Lund, Sweden – Xinnate is taking a major step toward reshaping the treatment landscape for Epidermolysis Bullosa with the FDA’s approval of its IND application for TCP-25 – positioning the company’s ...

SEATTLE — After its world premiere at the 2025 Tribeca Festival. The film, "Matter of Time," had its opening night here in West Seattle. The film is a powerful documentary that blends music, science ...

The FDA has approved an updated label for beremagene geperpavec-svdt (B-VEC), a topical gene therapy for dystrophic epidermolysis bullosa (DEB), which expands the indication from ages 6 months and ...

Historic moment underscores a decade of progress and the organization's urgent mission to cure Epidermolysis Bullosa and pioneer a path for the 400 million people affected by rare diseases worldwide.

BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, ...

Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis bullosa (EB), today launches a call for Basic Science ...

Inside a nautical-themed office building in Mount Pleasant featuring a giant tide gauge and metal fish sculptures, sit quiet offices where people are working to fight "the worst disease you have never ...

The FDA approved prademagene zamikeracel (Zevaskyn) for treating adults and children with the blistering wounds caused by recessive dystrophic epidermolysis bullosa (RDEB), Abeona Therapeutics ...